Advertisement

Recombinant Human Insulin-Like Growth Factor I: Effects in Normal Subjects and Implications for Use in Patients

  • Hans-Peter Guler
  • Katharina Wettstein
  • Werner Schurr
  • Jurgen Zapf
  • E. Rudolf Froesch
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 293)

Abstract

Two major forms of insulin-like growth factors (IGF-I and IGF-II) and their specific binding proteins have been detected in body fluids, including serum, cerebrospinal fluid, breast milk, lymph, and saliva. Extracts of almost any tissue reveal the presence of IGFs. Many cells in culture secret IGFs and various forms of their carrier proteins into the medium (1–3).

Keywords

Growth Hormone Growth Hormone Secretion Specific Binding Protein Dawn Phenomenon Snell Dwarf Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Daughaday WH, Rotwein P. Insulin-Like Growth Factors I and II Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations. Endocrine Rev 10:68–91, 1989.CrossRefGoogle Scholar
  2. 2.
    Humbel RE. Insulin-like Growth Factors I and II. Eur J Biochem 190:445–462, 1990.PubMedCrossRefGoogle Scholar
  3. 3.
    Sara VR, Hall K. Insulin-Like Growth Factors and Their Binding Proteins. Physiol Rev 70:591–614, 1990.PubMedGoogle Scholar
  4. 4.
    Froesch ER, Schmid Chr, Schwander J, Zapf J. Actions of Insulin-Like Growth Factors. Ann Rev Physiol 47:443–467, 1985.CrossRefGoogle Scholar
  5. 5.
    Hardouin S, Gourmelen M, Noguiez P, Seurin D, Roghani M, LeBouc Y, Povoa G, Merimee TJ, Hossenlopp P, Binoux M. Molecular Forms of Serum Insulin-Like Growth Factor (IGF)-Binding Proteins in Man: Relationships with Growth Hormone and IGFs and Physiological Significance. J Clin Endocrin Metabol 65:1291– 1301, 1989.CrossRefGoogle Scholar
  6. 6.
    Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-Like Growth factor I Stimulates Growth in Hypophysectomized Rats. Nature 796:252–253, 1982.CrossRefGoogle Scholar
  7. 7.
    Van Buul-Offers S, Ueda I, Van den Brande JL. Biosynthetic Somatomedin C (SM-C/IGF-I) Increases the Length and Weight of Snell Dwarf Mice. Pediatric Res 20:825–827, 1986.CrossRefGoogle Scholar
  8. 8.
    Guler HP, Zapf J, Scheiwiller E, Froesch ER. Recombinant Human Insulin-Like Growth Factor I Stimulates Growth and Has Distinct Effects on Organ Size in Hypophysectomized Rats. Proc. Natl. Acad. Sci. 85:4889–4893, 1988.PubMedCrossRefGoogle Scholar
  9. 9.
    Zapf J, Schmid C., Guler HP, Waldvogel M, Hauri C., Futo E, Hossenlopp P, Binoux M, Froesch ER. Regulation of Binding Proteins for Insulin-Like Growth Factors (IGF) in Man: Increased Expression of IGF Binding Protein-2 During IGF-I Treatment of Healthy Adults and in Patients with Extrapancreatic Tumor Hypoglycemia. J Clin Invest; 86:952–962, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE. IGF-I infusion into hypophysectomized or protein deprived rats induces specific IGF-binding proteins in serum. Endocrinology 125:2967–2972, 1989.PubMedCrossRefGoogle Scholar
  11. 11.
    Zapf J, Hauri C, Waldvogel M, Futo E, Hasler H, Binz K, Guler HP, Schmid Ch, Froesch ER. Recombiant human IGF-I its own specific carrier protein in hypophysectmoized and diabetic rats. Proc Natl Acad Sci 86: 3813–3817, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    Guler HP, Zapf J, Froesch ER. Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor in Healthy Adults. NEJM 317:137–140, 1987.PubMedCrossRefGoogle Scholar
  13. 13.
    Laron Z, Klinger B, Erster B, Anin S. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet II: 1170–1172, 1988.CrossRefGoogle Scholar
  14. 14.
    Takano K, Hizuka N, Asakawa K, Sukegawa I, Shizume K, Demura H. Effects of sc administration of rhIGF-I on normal human subjects. Endocrinol Japon 37:309–317, 1990.CrossRefGoogle Scholar
  15. 15.
    Leahy JL, Vandekerkhove KM. Insulin-Like Growth Factor-I at Physiological Concentrations Is a Potent Inhibitor of Insulin Secretion. Endocrinology 126:1593–1598, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Van Schravendijk C, Heylen L, Van Den Brande JL, Pipeleers D. Effects of Insulin and IGF-I on the Secretory Activity of Pancreatic B-Cells. Diabetologia 32:551A, 1989.Google Scholar
  17. 17.
    Guler HP, Schmid Ch, Zapf J, Froesch ER. Effects of recombinant human IGF-I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci 86:2868–2872, 1989.PubMedCrossRefGoogle Scholar
  18. 18.
    Keller S, Schmid Ch, Zapf J, Froesch ER. Inhibition of insulin degradation by insulin-like growth factors I and II in human hepatoma (HepG2) cells. Acta Endocrin 121:279–285, 1989.Google Scholar
  19. 19.
    Livingston N, Pollare T, Lithell H, Arner P. Characterisation of Insulin-Like Growth Factor I Receptor in Skeletal Muscles of Normal and Insulin Resistant Subjects. Diabetologia 31:871–877, 1988.PubMedCrossRefGoogle Scholar
  20. 20.
    Jacob R, Bowen L, Fryburg D, Fagin K, Tamborlane W, Shulman GI. Increased Metabolic Response to IGF-I in Insulin Resistant Diabetic BB Rats. Ann. Meeting Amer. Diab Assn., Detroit 1989, Abstract #261.Google Scholar
  21. 21.
    Dohm GL, Elton CW, Raju MS, Mooney ND, DiMarchi R, Pories WJ, Flickinger EG, Atkinson M, Caro JF. IGF-I stimulated glucose transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes 39: 1028–1032, 1990.PubMedCrossRefGoogle Scholar
  22. 22.
    Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L. Somatomedin-C Mediates Growth Hormone Netative Feedback by Effects on Both the Hypothalamus and the Pituitary. Science 212:1279–1281, 1981.PubMedCrossRefGoogle Scholar
  23. 23.
    Hiromi A, Molitch ME, Van Wyk JJ, Underwood LE. Human Growth Hormone and Somatomedin C Suppress the Spontaneous Release of Growth Hormone in Unanesthetized Rats. Endocrinology 113:1319, 1983.CrossRefGoogle Scholar
  24. 24.
    Yamashita S, Melmed S. Insulin-Like Growth Factor I Action on Rat Anterior Pituitary Cells: Suppression of Growth Hormone Secretion and Messenger Ribonucleic Acid Levels. Endocrinology 118:176–181, 1986.PubMedCrossRefGoogle Scholar
  25. 25.
    Morita S, Yamashita S, Melmed S. Insulin-Like Growth Factor I Action on Rat Anterior Pituitary Cells: Effects of Intracellular Messengers on Growth Hormone Secretion and Messenger Ribonucleic Acid Levels. Endocrinology 121: 2000–2006, 1987.PubMedCrossRefGoogle Scholar
  26. 26.
    Fagin JA, Brown A, Melmed S. Regulation of Pituitary Insulin-Like Growth Factor-I Messenger Ribonucleic Acid Levels in Rats Harboring Somatomammotropic Tumors: Implications for Growth Hormone Autoregulations. Endocrinology 122: 2204–2210, 1988.PubMedCrossRefGoogle Scholar
  27. 27.
    Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type I (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33:52–59, 1990.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Hans-Peter Guler
    • 2
  • Katharina Wettstein
    • 1
  • Werner Schurr
    • 3
  • Jurgen Zapf
    • 1
  • E. Rudolf Froesch
    • 1
  1. 1.Metabolic Unit, Department of MedicineUniversity HospitalZurichSwitzerland
  2. 2.Ciba-Geigy Corp.SummitUSA
  3. 3.Ciba-Geigy AGBasleSwitzerland

Personalised recommendations